The Oklahoma Shared Clinical and Translational Resources

The OSCTR is funded by the National Institutes of Health as part of its IDeA-CTR program. We have the mission to serve as a catalyst for clinical and translational research that improves health and healthcare for Oklahomans, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Clinical and Translational Science Institute

 

OCTSI is the home of the OSCTR, as well as clinical research services and dissemination and implementation resources to help improve the delivery of healthcare. 

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

Get More Information

 

Request Services

 

Find Other Researchers

 

Research Toolkit

 

Clinical Research in Oklahoma

 

Citing the OSCTR

Oklahoma Health Services Research Conference Registration Now Open!

Submitted by alex on

On behalf of the OCTSI and the Department of Medicine, we are pleased to announce the inaugural Oklahoma Health Services Research Conference! This event will showcase national leaders in health services research from outside institutions and across the University of Oklahoma Health Campus. This event is open to all faculty and trainees from all Colleges!

EVENT DATE: Tuesday, October 27, 2026, from 7:30 am to 4:30 pm 

2026 Oklahoma Conference for Statistics, Biostatistics and Data Science

Submitted by alex on

The 2026 Oklahoma Conference for Statistics, Biostatistics and Data Science is coming soon!

Location: Hudson College of Public Health Building, Room 150 (801 NE 13th Street, Oklahoma City, OK 73104)

Conference Date: October 26-27, 2026

Contact Person(s): Chao Xu chao-xu@ouhsc.edu

Registration Deadline: October 20, 2026

Registration Cost:

Subscribe to News

Recent Publications

IL-6 Receptor Antagonists and Severe Post-COVID-19 Outcomes: An Emulated Target Trial

medRxiv [Preprint]. 2026 Mar 2:2026.02.27.26347274. doi: 10.64898/2026.02.27.26347274.

ABSTRACT

BACKGROUND: Interleukin-6 (IL-6) is a cytokine that plays a key role in systemic hyperinflammation and may mediate the relationship between acute COVID-19 and severe long-term outcomes such as Long COVID or death. IL-6 modulating drugs may reduce patients' risk of severe post-COVID-19 outcomes.

Among individuals who die of COVID-19, is the percentage who had diabetes actually higher than in those dying of other viral infections?

Cardiovasc Diabetol Endocrinol Rep. 2026 Sep 15;12(1):61. doi: 10.1186/s40842-026-00325-0.

ABSTRACT

BACKGROUND: Early in the COVID-19 pandemic, mainstream news outlets reported that 30-40% of all coronavirus deaths in the United States occurred among individuals with diabetes. This statistic happens to reflect the approximate prevalence of diabetes in older adults, the age group at highest risk for mortality from COVID-19. To provide greater context to this statistic, we sought to quantify both the proportion of decedents from COVID-19 and from influenza who had diabetes.

Media

Copyright © 2026 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies